BEAM Stock Analysis: Buy, Sell, or Hold?
BEAM - Beam Therapeutics Inc. Common Stock
$31.17
-1.51 (-4.62%)
▼
5d:
-11.75%
30d:
+5.7%
90d:
+13.63%
WAIT
LOW Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 04, 2026
21d
Smart Money Accumulation
None View Scanner →
Strength: 5.9/10
Get Alerted When BEAM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: BEAM is down 11.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: BEAM is down 11.7% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: BEAM is currently trading at $31.17, which is considered slightly low relative to its 30-day fair value range of $30.53 to $35.44.
Technical Outlook: Technically, BEAM is in a uptrend. The price is currently testing key support at $30.78. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $51.36 (+57.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, BEAM is in a uptrend. The price is currently testing key support at $30.78. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $51.36 (+57.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$30.53 -
$35.44
Company Quality Score
49/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
Protect Your Profits
Holding BEAM? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.6%)
- BULLISH: Trading 57.2% below Wall St target ($51.36)
- WARNING: Recommendation downgraded due to -11.7% 5-day decline - wait for stabilization
Trading Range Analysis
30-Day Trading Range
$30.53 -
$35.44
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$30.78
Resistance Level
$38.26
Current Trend
Uptrend
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-6.91
Wall Street Target
$51.36
(+57.2%)
Revenue Growth (YoY)
324.9%
Profit Margin
-40.2%
Share & Embed Analysis
Last updated: July 13, 2026 3:33 PM ET
Data refreshes hourly during market hours. Next update: 4:33 PM
Data refreshes hourly during market hours. Next update: 4:33 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BEAM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
7
Sells
Net
INSIDERS SELLING
Recent Transactions
Amy Simon
SELL
6700 shares
2026-04-01
Christine Bellon
SELL
5956 shares
2026-04-01
Giuseppe Ciaramella
SELL
11810 shares
2026-04-01
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$52 | 62 BUY |
|
JAZZ
Jazz Pharmaceuticals PLC |
STRONG BUY
18 analysts |
$258 | 67 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 59 HOLD |
|
TVTX
Travere Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 54 HOLD |
|
XNCR
Xencor Inc |
STRONG BUY
12 analysts |
$28 | 61 BUY |
Advanced BEAM Option Strategies
Professional options setups generated by AI based on today's BEAM price and gamma walls.
